Vandetanib
Specifications
443913-73-3CAS Number
669-841-4EC Number
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amineIUPAC Name
C22H24BrFN4O2Chemical Formula
475.4 g/molMolecular Weight
Vandetanib; 443913-73-3; Zactima; ZD6474; Caprelsa; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; ZD-6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; ZD 6474; GNF-PF-2188; ZD-64; NSC-744325; NSC-760766; DTXSID1046681; YO460OQ37K; CHEBI:49960; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine; DTXCID9026681; 4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-; vandetanibum; RefChem:58965; AZD6474; L01XE12; vandetanib (zd6474); C22H24BrFN4O2; AZD-6474; MFCD07772346; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; CHEMBL24828; 338992-00-0; F9995-0087; Vandetanib [INN]; NCGC00167513-01; N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine; CAS-443913-73-3; UNII-YO460OQ37K; HSDB 8198; 2ivu; Vandetanib [USAN:INN:BAN:JAN]; Caprelsa (TN); CH 331; CH-331; Vandetanib (Zactima); Vandetanib (Standard); Kinome_3316; VANDETANIB [MI]; VANDETANIB [JAN]; VANDETANIB [USAN]; VANDETANIB [VANDF]; BDBM21; Vandetanib (ZD6474)?; SCHEMBL9044; VANDETANIB [MART.]; VANDETANIB [WHO-DD]; MLS006011672; Vandetanib (JAN/USAN/INN); GTPL5717; orb1225036; orb1307862; Vandetanib - Bio-X trade mark; SCHEMBL21067679; SCHEMBL21067681; SCHEMBL29351698; SCHEMBL29352879; VANDETANIB [ORANGE BOOK]; cid_3081361; EX-A422; UHTHHESEBZOYNR-UHFFFAOYSA-N; GLXC-90097; HMS3244K03; HMS3244K04; HMS3244L03; HMS3654E11; HMS3672C07; HMS5087C15; SMSSF-0113863; ZWB68349; Tox21_112511; BDBM50595124; EBC-07806; HY-10260R; NSC744325; NSC760766; NSC800961; s1046; AKOS015902350; Tox21_112511_1; AC-5251; CCG-269495; CS-0130; DB05294; FV28668; NSC 744325; NSC 760766; NSC-800961; SB16919; SDCCGSBI-0647658.P002; 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline; NCGC00167513-02; NCGC00167513-03; NCGC00167513-04; NCGC00167513-09; NCGC00167513-10; (4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine; 4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE; AS-11067; BP-44062; BV164508; HY-10260; SMR002530472; SY027438; NS00008846; SW218092-2; V0352; D06407; EN300-265835; SBI-0647658.0001; V-9402; AB01273969-01; AB01273969-02; AB01273969_04; F050800; SR-00000000462; Q7914515; SR-00000000462-2; BRD-K77625799-001-01-0; BRD-K77625799-001-07-7; Z2512943095; (4-bromo-2-fluorophenyl){6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]-4-quinazolinyl}amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxy]quinazoline; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[ (1-methylpiperidin-4-yl)methoxy]quinazoline; 4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline; 4-QUINAZOLINAMINE, N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYL-4- PIPERIDINYL)METHOXY)-; Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-; ZD6Synonyms
Products Containing Vandetanib
카프렐사정300밀리그램(반데타닙)카프렐사정100밀리그램(반데타닙)CAPRELSA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULACAPRELSA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULACAPRELSA 300 mg, comprimé pelliculéCAPRELSA 100 mg, comprimé pelliculéVANDETANIB - Catalent Pharma SolutionsVANDETANIB - Biotechnica DWCVANDETANIBVandetanibVandetanibVandetanib
Page 1 of 2
Companies Selling Vandetanib
HR
Hangzhou Royall Import & Export Co.,LtdChinaSD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaHT
Hefei TianRui Pharmaceutical Chemical Co., LtdChina
(주
(주)사노피-아벤티스코리아Republic of KoreaBS
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.ChinaAC
AFINE CHEMICALS LIMITEDBD
Biotechnica DWCAlgeria